In major news released today, Actinium Pharmaceuticals announced that the FDA has “granted orphan drug designation for Iomab-B, a radioimmuno-therapeutic that conditions relapsed and refractory Acute Myeloid Leukemia (AML) patients for a hematopoietic stem cell transplant (HSCT).”
The drug is key to condition patients undergoing a hematopoietic stem cell transplant, making it a significant announcement for the stem cell community.
To learn more, read the full press release below, printed with permission from Janet Vasquez, Managing Director/Founder of JV Public Relations NY and media contact for Actinium Pharmaceuticals, Inc. [Read more…]